Zhongxing Liao

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3460751/publications.pdf

Version: 2024-02-01

182	7,692	47006	66911
papers	citations	47 h-index	78 g-index

185	185	185	7770
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	On the interplay between dosiomics and genomics in radiation-induced lymphopenia of lung cancer patients. Radiotherapy and Oncology, 2022, 167, 219-225.	0.6	16
2	Radiation-Induced Cardiovascular Disease: Mechanisms, Prevention, and Treatment. Current Oncology Reports, 2022, 24, 543-553.	4.0	15
3	Radiation-Induced Esophagitis in Non-Small-Cell Lung Cancer Patients: Voxel-Based Analysis and NTCP Modeling. Cancers, 2022, 14, 1833.	3.7	9
4	A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma. Clinical Cancer Research, 2022, 28, 1792-1799.	7.0	39
5	Toward Improved Outcomes for Patients With Lung Cancer Globally: The Essential Role of Radiology and Nuclear Medicine. JCO Global Oncology, 2022, , .	1.8	1
6	Predictive performance of different NTCP techniques for radiation-induced esophagitis in NSCLC patients receiving proton radiotherapy. Scientific Reports, 2022, 12, .	3.3	4
7	Health Care Resource Utilization for Esophageal Cancer Using Proton versus Photon Radiation Therapy. International Journal of Particle Therapy, 2022, 9, 18-27.	1.8	1
8	Impact of intra-fractional motion on dose distributions in lung IMRT. Journal of Radiotherapy in Practice, 2021, 20, 12-16.	0.5	1
9	Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. Clinical Lung Cancer, 2021, 22, 225-233.e7.	2.6	2
10	Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Nonâ€“Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. Clinical Lung Cancer, 2021, 22, e451-e465.	2.6	26
11	Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes. Radiotherapy and Oncology, 2021, 154, 187-193.	0.6	25
12	Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. Journal of Thoracic Oncology, 2021, 16, 269-277.	1.1	23
13	New Data-Driven Gated PET/CT Free of Misregistration Artifacts. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1638-1646.	0.8	11
14	Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial. Neuro-Oncology, 2021, 23, 967-978.	1.2	15
15	The Reality of Randomized Controlled Trials for Assessing the Benefit of Proton Therapy: Critically Examining the Intent-to-Treat Principle in the Presence of Insurance Denial. Advances in Radiation Oncology, 2021, 6, 100635.	1.2	3
16	Effectively Conducting Oncology Clinical Trials During the COVID-19 Pandemic. Advances in Radiation Oncology, 2021, 6, 100676.	1.2	7
17	Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. Clinical and Translational Radiation Oncology, 2021, 28, 54-61.	1.7	5
18	Geometric and dosimetric accuracy of deformable image registration between averageâ€intensity images for 4DCTâ€based adaptive radiotherapy for nonâ€small cell lung cancer. Journal of Applied Clinical Medical Physics, 2021, 22, 156-167.	1.9	7

#	Article	IF	Citations
19	Radiation Pneumonitis in Thoracic Cancer Patients: Multi-Center Voxel-Based Analysis. Cancers, 2021, 13, 3553.	3.7	15
20	Probing thoracic dose patterns associated to pericardial effusion and mortality in patients treated with photons and protons for locally advanced non-small-cell lung cancer. Radiotherapy and Oncology, 2021, 160, 148-158.	0.6	12
21	Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2021, 22, e745-e755.	2.6	15
22	Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncology, The, 2021, 22, 1448-1457.	10.7	154
23	A Multi-Institutional Analysis of Radiation Dosimetric Predictors of Toxicity After Trimodality Therapy for Esophageal Cancer. Practical Radiation Oncology, 2021, 11, e415-e425.	2.1	10
24	Radiotherapy clinical trial enrollment during the COVID-19 pandemic. Acta OncolÃ³gica, 2021, 60, 312-315.	1.8	8
25	T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 719285.	4.8	6
26	Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. International Journal of Cancer, 2020, 146, 1359-1368.	5.1	55
27	Proton therapy for locally advanced non-small cell lung cancer. British Journal of Radiology, 2020, 93, 20190378.	2.2	15
28	Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 349-357.	0.8	27
29	Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC. Journal of Thoracic Oncology, 2020, 15, 101-109.	1.1	38
30	Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 100-107.	0.8	15
31	Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy. Clinical Cancer Research, 2020, 26, 2908-2920.	7.0	30
32	Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. Journal of Thoracic Oncology, 2020, 15, 248-257.	1.1	97
33	Modern Radiotherapy and Risk of Cardiotoxicity. Chemotherapy, 2020, 65, 65-76.	1.6	27
34	Development and application of an elastic net logistic regression model to investigate the impact of cardiac substructure dose on radiation-induced pericardial effusion in patients with NSCLC. Acta OncolÃ³gica, 2020, 59, 1193-1200.	1.8	6
35	Multi-institutional Evaluation of Curative Intent Chemoradiotherapy for Patients With Clinical T1N0 Esophageal Adenocarcinoma. Advances in Radiation Oncology, 2020, 5, 951-958.	1.2	0
36	Radiation Oncology Strategies to Flatten the Curve During the Coronavirus Disease 2019 (COVID-19) Pandemic: Experience From a Large Tertiary Cancer Center. Advances in Radiation Oncology, 2020, 5, 567-572.	1.2	12

#	Article	IF	Citations
37	Cancer associated macrophage-like cells and prognosis of esophageal cancer after chemoradiation therapy. Journal of Translational Medicine, 2020, 18, 413.	4.4	24
38	Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19. Radiotherapy and Oncology, 2020, 148, 252-257.	0.6	20
39	Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak. Lung Cancer, 2020, 146, 230-235.	2.0	20
40	Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. Journal of Clinical Oncology, 2020, 38, 1569-1579.	1.6	158
41	Anatomic change over the course of treatment for nonâ€“small cell lung cancer patients and its impact on intensity-modulated radiation therapy and passive-scattering proton therapy deliveries. Radiation Oncology, 2020, 15, 55.	2.7	16
42	Extracellular vesicle tetraspanin-8 level predicts distant metastasis in nonâ€“small cell lung cancer after concurrent chemoradiation. Science Advances, 2020, 6, eaaz6162.	10.3	42
43	Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head and Neck, 2020, 42, 1939-1953.	2.0	29
44	Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer. Journal of Thoracic Oncology, 2020, 15, 1682-1690.	1.1	63
45	A Mindfulness-Based Intervention as a Supportive Care Strategy for Patients with Metastatic Non-Small Cell Lung Cancer and Their Spouses: Results of a Three-Arm Pilot Randomized Controlled Trial. Oncologist, 2020, 25, e1794-e1802.	3.7	35
46	Thoracic Radiation Oncology Clinical Trial Accrual and Reasons for Nonenrollment: Results of a Large, Prospective, Multiyear Analysis. International Journal of Radiation Oncology Biology Physics, 2020, 107, 897-908.	0.8	2
47	Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure. Radiotherapy and Oncology, 2020, 145, 178-185.	0.6	20
48	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. Nature Cancer, 2020, 1, 176-183.	13.2	201
49	Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Nonâ€“Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clinical Lung Cancer, 2020, 21, e294-e301.	2.6	10
50	Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer. JAMA Network Open, 2020, 3, e203277.	5.9	15
51	NTCP Models for Severe Radiation Induced Dermatitis After IMRT or Proton Therapy for Thoracic Cancer Patients. Frontiers in Oncology, 2020, 10, 344.	2.8	22
52	Lymanâ€“Kutcherâ€“Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy. Radiotherapy and Oncology, 2020, 146, 200-204.	0.6	12
53	Protocol-in-a-Day Workshop: A Lean Approach to Clinical Trial Development and Focus on Junior Faculty Development. Advances in Radiation Oncology, 2019, 4, 439-442.	1.2	0
54	Enhancing clinical trial enrollment at MD Anderson Cancer Center satellite community campuses. Acta OncolÃ³gica, 2019, 58, 1135-1137.	1.8	2

#	Article	IF	Citations
55	The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy. Radiotherapy and Oncology, 2019, 133, 9-15.	0.6	50
56	Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy. Clinical and Translational Radiation Oncology, 2019, 17, 17-23.	1.7	24
57	Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases. JAMA Oncology, 2019, 5, 872.	7.1	146
58	Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. Radiotherapy and Oncology, 2019, 136, 136-142.	0.6	21
59	Spatial Dose Patterns Associated With Radiation Pneumonitis in a Randomized Trial Comparing Intensity-Modulated Photon Therapy With Passive Scattering Proton Therapy for Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1124-1132.	0.8	37
60	The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care. International Journal of Radiation Oncology Biology Physics, 2019, 104, 724-733.	0.8	47
61	Patterns of Local-Regional Failure After Intensity Modulated Radiation Therapy or Passive Scattering Proton Therapy With Concurrent Chemotherapy for Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 103, 123-131.	0.8	16
62	Potential for Improvements in Robustness and Optimality of Intensity-Modulated Proton Therapy for Lung Cancer with 4-Dimensional Robust Optimization. Cancers, 2019, 11, 35.	3.7	27
63	Validation of Effective Dose as a Better Predictor of Radiation Pneumonitis Risk Than Mean Lung Dose: Secondary Analysis of a Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2019, 103, 403-410.	0.8	23
64	Automatic segmentation of cardiac substructures from noncontrast CT images: accurate enough for dosimetric analysis?. Acta OncolÃ³gica, 2019, 58, 81-87.	1.8	18
65	The Road Less Traveled: Should We Omit Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer?. Clinical Lung Cancer, 2018, 19, 289-293.	2.6	3
66	Clinical and Dosimetric Factors Predicting Grade â‰¥2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 101, 919-926.	0.8	34
67	Out of the darkness and into the light: New strategies for improving treatments for locally advanced non-small cell lung cancer. Cancer Letters, 2018, 421, 59-62.	7.2	8
68	Differences in lung injury after IMRT or proton therapy assessed by 18FDG PET imaging. Radiotherapy and Oncology, 2018, 128, 147-153.	0.6	17
69	Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. International Journal of Radiation Oncology Biology Physics, 2018, 100, 730-737.	0.8	27
70	Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 558-563.	0.8	55
71	Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Nonâ€“Small Cell Lung Cancer after Definitive Radiotherapy. Journal of Thoracic Oncology, 2018, 13, 660-675.	1.1	29
72	Cost Analysis of PET/CT Versus CT as Surveillance for Stage III Nonâ€“Small-Cell Lung Cancer After Definitive Radiation Therapy. Clinical Lung Cancer, 2018, 19, e517-e528.	2.6	6

#	Article	IF	Citations
73	Impact of Spot Size and Spacing on the Quality of Robustly Optimized Intensity Modulated Proton Therapy Plans for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 479-489.	0.8	44
74	Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. Quality of Life Research, 2018, 27, 1563-1570.	3.1	12
75	Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Annals of Surgery, 2018, 268, 289-295.	4.2	32
76	Reirradiation of thoracic cancers with intensity modulated proton therapy. Practical Radiation Oncology, 2018, 8, 58-65.	2.1	34
77	Radiation Dose, Local Disease Progression, and Overall Survival in Patients With Inoperable Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 100, 452-461.	0.8	11
78	Pilot Testing of a Brief Couple-Based Mind-Body Intervention for Patients With Metastatic Non-Small Cell Lung Cancer and Their Partners. Journal of Pain and Symptom Management, 2018, 55, 953-961.	1.2	13
79	Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 1813-1822.	1.6	243
80	Particle therapy in non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, 141-152.	2.8	16
81	Survival Patterns for Patients with Resected N2 Nonâ€“Small Cell Lung Cancer and Postoperative Radiotherapy: A Prognostic Scoring Model and Heat Map Approach. Journal of Thoracic Oncology, 2018, 13, 1968-1974.	1.1	36
82	Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Network Open, 2018, 1, e181390.	5.9	48
83	Functional promoter rs189037 variant of ATM is associated withÂdecrease in lung diffusing capacity after irradiation for nonâ€“small-cell lung cancer. Chronic Diseases and Translational Medicine, 2018, 4, 59-66.	1.2	2
84	Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer. Lung Cancer, 2018, 122, 60-66.	2.0	38
85	DNA repair capacity correlates with standardized uptake values from 18 F-fluorodeoxyglucose positron emission tomography/CT in patients with advanced nonâ€“small-cell lung cancer. Chronic Diseases and Translational Medicine, 2018, 4, 109-116.	1.2	1
86	Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nature Communications, 2018, 9, 3114.	12.8	122
87	A research protocol for a pilot randomized controlled trial designed to examine the feasibility of a couple-based mind-body intervention for patients with metastatic lung cancer and their partners. Pilot and Feasibility Studies, 2018, 4, 37.	1.2	9
88	Nomograms incorporating genetic variants in <scp>BMP</scp>/Smad4/Hamp pathway to predict disease outcomes after definitive radiotherapy for nonâ€small cell lung cancer. Cancer Medicine, 2018, 7, 2247-2255.	2.8	4
89	The utility of quantitative <scp>CT</scp> radiomics features for improved prediction of radiation pneumonitis. Medical Physics, 2018, 45, 5317-5324.	3.0	81
90	Trends and Outcomes of Proton Radiation Therapy Use for Nonâ€“Small Cell Lung Cancer. International Journal of Particle Therapy, 2018, 5, 18-27.	1.8	2

#	Article	IF	Citations
91	Considerations in randomized trials to test technologies. Journal of Thoracic Disease, 2018, 10, S3308-S3308.	1.4	0
92	A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients. International Journal of Radiation Oncology Biology Physics, 2017, 98, 820-828.	0.8	28
93	Long-Term Outcomes of Salvage Stereotactic AblativeÂRadiotherapy for Isolated Lung Recurrence of Nonâ€“Small Cell Lung Cancer: A Phase II Clinical Trial. Journal of Thoracic Oncology, 2017, 12, 983-992.	1.1	51
94	The Pulmonary Fibrosis Associated MUC5B Promoter Polymorphism Is Prognostic of the Overall Survival in Patients with Nonâ€“Small Cell Lung Cancer (NSCLC) Receiving Definitive Radiotherapy. Translational Oncology, 2017, 10, 197-202.	3.7	7
95	Delta-radiomics features for the prediction of patient outcomes in nonâ€“small cell lung cancer. Scientific Reports, 2017, 7, 588.	3.3	254
96	Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Radiotherapy and Oncology, 2017, 123, 376-381.	0.6	81
97	¹⁸F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma. Journal of Nuclear Medicine, 2017, 58, 1756-1763.	5.0	18
98	Association of lung fluorodeoxyglucose uptake with radiation pneumonitis after concurrent chemoradiation for non-small cell lung cancer. Clinical and Translational Radiation Oncology, 2017, 4, 1-7.	1.7	10
99	Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 70-79.	0.8	52
100	Recursive Partitioning Analysis Identifies Pretreatment Risk Groups for the Utility of Induction Chemotherapy Before Definitive Chemoradiation Therapy in Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 407-416.	0.8	6
101	Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis. Radiotherapy and Oncology, 2017, 123, 346-354.	0.6	62
102	7â€year followâ€up after stereotactic ablative radiotherapy for patients with stage I nonâ€“small cell lung cancer: Results of a phase 2 clinical trial. Cancer, 2017, 123, 3031-3039.	4.1	125
103	A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer. Journal of Thoracic Oncology, 2017, 12, 1001-1010.	1.1	16
104	Outcomes and toxicity following high-dose radiation therapy in 15 fractions for non-small cell lung cancer. Practical Radiation Oncology, 2017, 7, 433-441.	2.1	12
105	Cardiac atlas development and validation for automatic segmentation of cardiac substructures. Radiotherapy and Oncology, 2017, 122, 66-71.	0.6	76
106	Patterns and correlates of treatment failure in relation to isodose distribution in non-small cell lung cancer: An analysis of 1522 patients in the modern era. Radiotherapy and Oncology, 2017, 125, 325-330.	0.6	0
107	Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survivalâ€”The University of Texas MD Anderson Cancer Center experience. Cancer, 2017, 123, 4106-4113.	4.1	118
108	Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2017, 3, e172032.	7.1	119

#	Article	IF	Citations
109	Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study. Advances in Radiation Oncology, 2017, 2, 316-324.	1.2	14
110	Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 99, 667-676.	0.8	79
111	Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer. Clinical and Experimental Metastasis, 2017, 34, 315-322.	3.3	5
112	A Novel Methodology using CT Imaging Biomarkers to Quantify Radiation Sensitivity in the Esophagus with Application to Clinical Trials. Scientific Reports, 2017, 7, 6034.	3.3	15
113	Dosimetric comparison of the helical tomotherapy, volumetric-modulated arc therapy and fixed-field intensity-modulated radiotherapy for stage IIB-IIIB non-small cell lung cancer. Scientific Reports, 2017, 7, 14863.	3.3	13
114	Differences in Normal Tissue Response in the Esophagus Between Proton and Photon Radiation Therapy for Non-Small Cell Lung Cancer Using InÂVivo Imaging Biomarkers. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1013-1020.	0.8	5
115	The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiotherapy and Oncology, 2017, 124, 318-324.	0.6	47
116	Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. International Journal of Radiation Oncology Biology Physics, 2017, 97, 770-777.	0.8	16
117	Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 141-148.	2.6	12
118	Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. Practical Radiation Oncology, 2017, 7, e195-e203.	2.1	44
119	The Potential of Heavy-Ion Therapy to Improve Outcomes for Locally Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2017, 7, 201.	2.8	5
120	Blood-based biomarkers for precision medicine in lung cancer: precision radiation therapy. Translational Lung Cancer Research, 2017, 6, 661-669.	2.8	10
121	Polymorphisms in BMP2/BMP4, with estimates of mean lung dose, predict radiation pneumonitis among patients receiving definitive radiotherapy for non-small cell lung cancer. Oncotarget, 2017, 8, 43080-43090.	1.8	9
122	Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. Cancer, 2016, 122, 917-928.	4.1	75
123	Prospective Study of Patient-Reported Symptom Burden in Patients With Nonâ€“Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. Journal of Pain and Symptom Management, 2016, 51, 832-838.	1.2	27
124	Potential Use of 18F-fluorodeoxyglucose Positron Emission Tomographyâ€“Based Quantitative Imaging Features for Guiding Dose Escalation inÂStage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 368-376.	0.8	13
125	Prognosis and predictors of site of first metastasis after definitive radiation therapy for non-small cell lung cancer. Acta OncolÃ³gica, 2016, 55, 1022-1028.	1.8	22
126	Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation. Radiotherapy and Oncology, 2016, 119, 495-500.	0.6	75

#	Article	IF	Citations
127	Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer. Radiotherapy and Oncology, 2016, 121, 70-74.	0.6	12
128	18F-Fluorodeoxyglucose Positron Emission Tomography Can Quantify and Predict Esophageal Injury During Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 670-678.	0.8	17
129	In Reply to Jin etÂal. International Journal of Radiation Oncology Biology Physics, 2016, 96, 481-482.	0.8	1
130	Single Nucleotide Polymorphisms in CBLB, aÂRegulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 253-262.e5.	2.6	16
131	Objectively Quantifying Radiation Esophagitis With Novel Computed Tomographyâ€“Based Metrics. International Journal of Radiation Oncology Biology Physics, 2016, 94, 385-393.	0.8	15
132	Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 523-533.	0.8	103
133	Stage III Nonâ€“Small Cell Lung Cancer: Prognostic Value of FDG PET Quantitative Imaging Features Combined with Clinical Prognostic Factors. Radiology, 2016, 278, 214-222.	7.3	71
134	Lung Size and the Risk of Radiation Pneumonitis. International Journal of Radiation Oncology Biology Physics, 2016, 94, 377-384.	0.8	32
135	Novel Hybrid Scattering- and Scanning-Beam Proton Therapy Approach. International Journal of Particle Therapy, 2016, 3, 37-50.	1.8	2
136	Use of Simultaneous Radiation Boost Achieves High Control Rates in Patients With Nonâ€“Small-Cell Lung Cancer Who Are Not Candidates for Surgery or Conventional Chemoradiation. Clinical Lung Cancer, 2015, 16, 156-163.	2.6	31
137	Early experience with intensity modulated proton therapy for lung-intact mesothelioma: A case series. Practical Radiation Oncology, 2015, 5, e345-e353.	2.1	40
138	Incidental Receipt of Cardiac Medications and Survival Outcomes Among Patients With Stage III Nonâ€“Small-Cell Lung Cancer After Definitive Radiotherapy. Clinical Lung Cancer, 2015, 16, 128-136.	2.6	32
139	Robust optimization in intensity-modulated proton therapy to account for anatomy changes in lung cancer patients. Radiotherapy and Oncology, 2015, 114, 367-372.	0.6	72
140	Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage IIâ€“III inoperable non-small cell lung cancer. Radiotherapy and Oncology, 2015, 115, 367-372.	0.6	82
141	Impact of respiratory motion on worst-case scenario optimized intensity modulated proton therapy for lung cancers. Practical Radiation Oncology, 2015, 5, e77-e86.	2.1	75
142	Technical Note: A Monte Carlo study of magneticâ€fieldâ€induced radiation dose effects in mice. Medical Physics, 2015, 42, 5510-5516.	3.0	13
143	Hemithoracic Intensity Modulated Radiation Therapy After Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Toxicity, Patterns of Failure, and a Matched Survival Analysis. International Journal of Radiation Oncology Biology Physics, 2015, 91, 149-156.	0.8	52
144	A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. Journal of Gastrointestinal Oncology, 2015, 6, 45-52.	1.4	18

#	Article	IF	Citations
145	Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. Radiotherapy and Oncology, 2014, 113, 379-384.	0.6	26
146	Association Between White Blood Cell Count Following Radiation Therapy With Radiation Pneumonitis in Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 319-325.	0.8	16
147	Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. Practical Radiation Oncology, 2014, 4, e259-e268.	2.1	56
148	Stereotactic ablative radiotherapy (SABR) using 70Gy in 10 fractions for non-small cell lung cancer: Exploration of clinical indications. Radiotherapy and Oncology, 2014, 112, 256-261.	0.6	78
149	Prognostic Value and Reproducibility ofÂPretreatment CT Texture Features in Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, 834-842.	0.8	170
150	Clinical Implementation of Intensity Modulated Proton Therapy for Thoracic Malignancies. International Journal of Radiation Oncology Biology Physics, 2014, 90, 809-818.	0.8	125
151	Propensity Scoreâ€“Matched Analysis of Comprehensive Local Therapy for Oligometastatic Non-Small Cell Lung Cancer That Did Not Progress After Front-Line Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, 850-857.	0.8	61
152	Definitive Reirradiation for Locoregionally Recurrent Non-Small Cell Lung Cancer With Proton Beam Therapy or Intensity Modulated Radiation Therapy: Predictors of High-Grade Toxicity and Survival Outcomes. International Journal of Radiation Oncology Biology Physics, 2014, 90, 819-827.	0.8	71
153	Radiogenomics: Radiobiology Enters the Era of Big Data and Team Science. International Journal of Radiation Oncology Biology Physics, 2014, 89, 709-713.	0.8	99
154	Lymphopenia Association With Gross Tumor Volume and Lung V5 and Its Effects on Non-Small Cell Lung Cancer Patient Outcomes. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1084-1091.	0.8	285
155	On the interplay effects with proton scanning beams in stage III lung cancer. Medical Physics, 2014, 41, 021721.	3.0	87
156	Acute phase response before treatment predicts radiation esophagitis in non-small cell lung cancer. Radiotherapy and Oncology, 2014, 110, 493-498.	0.6	11
157	Genetic variants of the LIN28B gene predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. European Journal of Cancer, 2014, 50, 1706-1716.	2.8	38
158	International Outreach: What Is the Responsibility of ASTRO and the Major International Radiation Oncology Societies?. International Journal of Radiation Oncology Biology Physics, 2014, 89, 481-484.	0.8	11
159	Re-evaluating the Optimal Radiation Dose for Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2014, 9, 1398-1405.	1.1	55
160	Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Medical Dosimetry, 2013, 38, 442-447.	0.9	19
161	Effects of Respiratory Motion on Passively Scattered Proton Therapy Versus Intensity Modulated Photon Therapy for Stage III Lung Cancer: Are Proton Plans More Sensitive to Breathing Motion?. International Journal of Radiation Oncology Biology Physics, 2013, 87, 576-582.	0.8	35
162	Predicting Pneumonitis Risk: A Dosimetric Alternative to Mean Lung Dose. International Journal of Radiation Oncology Biology Physics, 2013, 85, 522-527.	0.8	31

#	Article	IF	Citations
163	What Would Be the Most Appropriateî±/Î²Ratio in the Setting of Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancer. BioMed Research International, 2013, 2013, 1-8.	1.9	23
164	Propensity Score-based Comparison of Long-term Outcomes With 3-Dimensional Conformal Radiotherapy vs Intensity-Modulated Radiotherapy for Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, 1078-1085.	0.8	230
165	Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer, 2012, 118, 2632-2640.	4.1	176
166	Status of particle therapy for lung cancer. Acta OncolÃ³gica, 2011, 50, 745-756.	1.8	32
167	Functional Polymorphisms of Base Excision Repair Genes XRCC1 and APEX1 Predict Risk of Radiation Pneumonitis in Patients With Nonâ€“Small Cell Lung Cancer Treated With Definitive Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, e67-e73.	0.8	63
168	Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer, 2011, 117, 3004-3013.	4.1	117
169	Patterns of Care and Locoregional Treatment Outcomes in Older Esophageal Cancer Patients: The SEER-Medicare Cohort. International Journal of Radiation Oncology Biology Physics, 2009, 74, 482-489.	0.8	51
170	Risk Factors for Pericardial Effusion in Inoperable Esophageal Cancer Patients Treated With Definitive Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2008, 70, 707-714.	0.8	171
171	Cyclo-Oxygenase-2 and its Inhibition in Cancer. Drugs, 2007, 67, 821-845.	10.9	65
172	Initial Evaluation of Treatment-Related Pneumonitis in Advanced-Stage Nonâ€“Small-Cell Lung Cancer Patients Treated With Concurrent Chemotherapy and Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 68, 94-102.	0.8	269
173	Evaluation of conventional radiotherapy vs. conformal radiotherapy in the treatment of non-small-cell lung cancer after surgical resection. Chinese-German Journal of Clinical Oncology, 2007, 6, 514-518.	0.1	0
174	Polymorphism at the 3â€²-UTR of the thymidylate synthase gene: A potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. International Journal of Radiation Oncology Biology Physics, 2006, 64, 700-708.	0.8	11
175	A Phase I Clinical Trial of Thoracic Radiotherapy and Concurrent Celecoxib for Patients with Unfavorable Performance Status Inoperable/Unresectable Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 3342-3348.	7.0	83
176	Dosimetric benefits of respiratory gating: a preliminary study. Journal of Applied Clinical Medical Physics, 2004, 5, 1-9.	1.9	15
177	COX-2 and its inhibition as a molecular target in the prevention and treatment of lung cancer. Expert Review of Anticancer Therapy, 2004, 4, 543-560.	2.4	31
178	Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1484-1493.	0.8	47
179	Role of Cyclooxygenase-2 Inhibitors in Combination with Radiation Therapy in Lung Cancer. Clinical Lung Cancer, 2003, 4, 356-365.	2.6	17
180	Combination of a COX-2 Inhibitor With Radiotherapy or Radiochemotherapy in the Treatment of Thoracic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, S85-S91.	1.3	16

#	Article	IF	Citations
181	Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2002, 53, 558-565.	0.8	13
182	Esophageal Adenocarcinoma. , 0, , 31-113.		0